Breaking News Instant updates and real-time market news.

IPXL

Impax

$13.75

0.225 (1.66%)

11:50
12/22/16
12/22
11:50
12/22/16
11:50

Impax could have significant upside if sold, says Deutsche Bank

Deutsche Bank analysts said it would be natural for investors to be concerned about Impax's near-term results and outlook after the company's CEO change, but also "intrigued" by the potential for the company to explore its options. While maintaining a Hold rating on the stock and noting they are not suggesting the company is about to be sold, the firm also said a sum-of-the-parts analysis suggests minimal downside and significant upside potential if the company were to be sold. Using historical M&A comparisons, Deutsche said Impax could be valued in a wide range from $22 to $41 per share in a theoretical takeover deal.

IPXL Impax
$13.75

0.225 (1.66%)

11/07/16
11/07/16
DOWNGRADE
Target $19

Underperform
Impax downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Impax to Underperform from Neutral and lowered its price target to $19 from $29. Analyst Sumant Kulkarni believes Impax could be at risk of achieving its 2016 earnings outlook of $1.57-$1.70 given a lot needs to go right to execute against its outlook including significant growth in generics and recently acquired products from Teva/Allergan. He believes investors could "shoot first, ask later" when it reports on Wednesday given sentiment in the Specialty Pharma environment and a strong 2016 outlook is crucial.
11/10/16
LEER
11/10/16
NO CHANGE
Target $15
LEER
Market Perform
Impax price target lowered to $15 from $24 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Impax to $15 from $24 after Q3 results for the company were relatively in line, but management dramatically reduced sales and EPS guidance reflecting continued competitive pressures in the U.S. generic space. The analyst reiterates a Market Perform rating on the shares.
11/11/16
UBSW
11/11/16
NO CHANGE
Target $12
UBSW
Sell
Impax price target lowered to $12 from $21 Impax at UBS
UBS analyst Marc Goodman lowered his price target on Impax (IPXL) to $12 from $21 as he believes the company's fundamentals continue to deteriorate. The analyst believes the company overpaid for Teva's (TEVA) products and due to price concessions is now estimating revenues to be about 50% of his previous estimate. Goodman reiterated his Sell rating on Impax shares.
11/14/16
WBTH
11/14/16
DOWNGRADE
WBTH
Hold
Impax downgraded earlier to Hold from Buy at WallachBeth

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.